Rasagiline mesylate Tablets

Name:Rasagiline mesylate Tablets

Specification:1mg

【Approval Number】State Drug Administration：H20243701

【Indication】

This product is suitable for monotherapy in patients with primary Parkinson's disease and for combination therapy (in combination with levodopa) in patients with end-dose fluctuations.

【Usage and dosage】

Oral administration. The dosage is 1mg once daily, regardless of whether it is combined with levodopa.

The most commonly reported adverse reactions were: headache, depression, dizziness, and influenza (influenza and rhinitis) during monotherapy; Dysphoria, orthostatic hypotension, falls, abdominal pain, nausea and vomiting, and dry mouth during levodopa therapy.